Notably, this alteration was consistent with that observed in the Western blot, i.e., a greatly decreased GAPDH (M.W. 37 kDa) in high-dose (2.0 mg/g) dasatinib-treated tumor (Figure 4, left panel). This evidence concerns the gene GAPDH and neoplasm.